KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.910
-0.360 (-2.93%)
As of 2:21PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.270
Open12.290
Bid11.970 x 1000
Ask11.990 x 3000
Day's Range11.435 - 12.347
52 Week Range9.000 - 21.710
Volume346,159
Avg. Volume695,618
Market Cap721.31M
Beta (3Y Monthly)4.41
PE Ratio (TTM)N/A
EPS (TTM)-2.814
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.20
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Karyopharm also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes.

  • GlobeNewswire13 days ago

    Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the “Notes”) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Subject to certain conditions, on or after October 15, 2022, Karyopharm may redeem for cash all or a portion of the Notes. The Notes will be convertible at the option of holders of the Notes, upon satisfaction of certain conditions and during certain periods, into cash, shares of Karyopharm’s common stock, or a combination of cash and shares of Karyopharm’s common stock, at Karyopharm’s option. The interest rate, conversion rate, conversion price and certain other terms of the Notes will be determined at the time of pricing of the offering.

  • GlobeNewswire17 days ago

    U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) seeking accelerated approval for selinexor, its first in class, oral SINE compound, as a new treatment for patients with penta-refractory multiple myeloma.  The FDA also granted Karyopharm’s request for Priority Review and assigned an action date of April 6, 2019 under the Prescription Drug User-Fee Act (PDUFA).  In its acceptance letter, the FDA has stated that it is currently planning to hold an advisory committee meeting to discuss this application.

  • GlobeNewswire21 days ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 108,900 shares of Karyopharm’s common stock to thirteen newly-hired employees, with a grant date of September 28, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $17.03 per share, the closing price of Karyopharm’s common stock on September 28, 2018.

  • GlobeNewswire27 days ago

    Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., Sept. 25, 2018 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management.

  • GlobeNewswirelast month

    Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology

    --Two Oral Presentations Highlighting Previously Reported Phase 2 b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2 b SADAL Data in Patients with Relapsed or Refractory Diffuse ...

  • Benzingalast month

    The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

    A roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 13.) Abbott Laboratories (NYSE: ABT ) Baxter International Inc ...

  • GlobeNewswirelast month

    Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting

    --Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle of Treatment--. --Median Survival of ...

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 62,500 shares of Karyopharm’s common stock to eight newly-hired employees, with a grant date of August 31, 2018. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $21.05 per share, the closing price of Karyopharm’s common stock on August 31, 2018.

  • GlobeNewswire2 months ago

    Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Carsten Thiel, Ph.D., to its Board of Directors. Dr. Thiel is currently Chief Executive Officer of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...

  • GlobeNewswire2 months ago

    Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., Aug. 29, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that members of the Company’ s management team will participate in the following upcoming ...

  • The Wall Street Journal2 months ago

    Karyopharm Therapeutics Ramps Up Hiring Ahead of Potential FDA Approval

    , is preparing to expand the biotech company’s finance team as it nears potential approval for a cancer treatment. As Karyopharm transitions from drug development to the commercial expansion phase, Mr. Falvey is looking to hire people who can contribute across various departments. “We are going through a dramatic transformation,” Mr. Falvey said.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within FORTERRA INC, Baytex Energy, MAG Silver, Bojangles', Ciner Resources LP, and Karyopharm Therapeutics — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FORTERRA ...

  • Barrons.com2 months ago

    [$$] Papa John's and 3 Other Small-Cap Value Plays

    Stocks that are sparsely covered by Wall Street analysts deserve some added attention from investors, according to new research from investment bank Jefferies. If Karyopharm’s drug, Selinexor, can gain accelerated approval for patients who have gone through most other treatments, it could come to market next year, with longer-term potential for expanded use.

  • Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

    Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 21.05% and 233.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Karyopharm Therapeutics: 2Q Earnings Snapshot

    The Newton, Massachusetts-based company said it had a loss of 60 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress

    --Completed Rolling Submission of a New Drug Application to FDA Seeking Accelerated Approval for Selinexor As a New Treatment for Patients with Penta-Refractory Multiple Myeloma--. --On Track to Report ...

  • ACCESSWIRE2 months ago

    Karyopharm Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Karyopharm Therapeutics, Inc. (NASDAQ: KPTI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM ...

  • GlobeNewswire3 months ago

    Karyopharm Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

    --Company to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Recent Business Developments on Tuesday, August 7, 2018 at 8:30 a.m. ET--. NEWTON, Mass., Aug. 06, 2018-- Karyopharm ...

  • GlobeNewswire3 months ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 196,500 shares of Karyopharm’s common stock to fourteen newly-hired employees, with a grant date of July 31, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $17.78 per share, the closing price of Karyopharm’s common stock on July 31, 2018.

  • GlobeNewswire3 months ago

    Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., Aug. 02, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that members of the Company’ s management team will participate in the following upcoming ...

  • GlobeNewswire3 months ago

    Karyopharm Appoints Ian Karp as Vice President, Investor and Public Relations

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Ian Karp as Vice President, Investor and Public Relations.  In this role, Mr. Karp will lead all of the Company’s corporate communications activities, including corporate visibility, financial communications, and media and investor relations. “Ian is a driven, forward-thinking communications leader with exceptional experience in relationship building, as well as with financial and corporate messaging,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm.  “He brings a wealth of industry experience, having served in senior leadership roles for several commercial-stage, global pharmaceutical companies, and successfully leading key strategic and operational activities.

  • Karyopharm Initiates NDA Submission Process for Selinexor
    Zacks3 months ago

    Karyopharm Initiates NDA Submission Process for Selinexor

    Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.